ClearBridge Investments, an investment management company, released its “ClearBridge Aggressive Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark index, Russell 3000 Growth Index, in the third quarter. The healthcare sector was the primary contributor to the strategy’s performance, while communication services detracted from the performance. In addition, please check the fund’s top five holdings to know its best picks in 2022.
ClearBridge Investments highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the Q3 2022 investor letter. Headquartered in Boston, Massachusetts, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company. On November 4, 2022, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock closed at $308.82 per share. One-month return of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 4.85% and its shares gained 60.65% of their value over the last 52 weeks. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has a market capitalization of $79.271 billion.
ClearBridge Investments made the following comment about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its Q3 2022 investor letter:
“Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which has developed the leading treatments for cystic fibrosis, also saw meaningful positive developments in its pipeline in the third quarter around areas like pain, diabetes and blood disorders. Vertex has been able to consistently grow revenues and earnings through the latest period of economic headwinds, enabling investment in R&D to target treatments in these new areas.”
Billion Photos/Shutterstock.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of the second quarter, which was 49 in the previous quarter.
We discussed Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in another article and shared the best pharma stocks to buy. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
- 10 Best Slow Growth Stocks To Buy
- 12 Non REIT Dividend Stocks To Buy
- 15 Best Strong Buy Stocks To Invest In
Disclosure: None. This article is originally published at Insider Monkey.